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ABSTRACT
Background and Objectives: Therapy-resistant immune
thrombocytopenia (ITP) is the most frequent indication of
laparoscopic splenectomy (LS). It ensures the best results
for this disease compared with possible second-line phar-
macologic therapies. Therefore, learning about the safety
of the surgical method and its long-term efficacy is impor-
tant, as is selecting patients who respond to surgical treat-
ment. Our purpose was to analyze the safety of LS and the
short-and long-term prognostic significance of known
perioperative parameters.
Methods: We performed 40 LSs for ITP from January 1,
2000, to January 1, 2015. We analyzed the roles of the
perioperative parameters by using evidence-based guide-
lines.
Results: Complete response (CR; platelet count over
100  109/L) occurred in 28 cases (70%) and partial
response (PR; platelet count between 30 and 100 109/L)
in 5 cases (12.5%). Below the age of 50, 9% (2/22) of the
patients had no response (NR; platelet count not increas-
ing over 30  109/L), 28% (5/18) over the age of 50 (P 
.023) had no response. In the steroid-refractory group,
30% did not respond, whereas 100% of the steroid-depen-
dent patients had a CR (NR: 7/23 steroid refractory vs 0/17
steroid dependent; P  .027). The patients were followed
up for a mean of 10.9  6.9 years, and a long-term
response (LTR) was detected in 21 of the responders (n 
33). Of the patients who originally had a CR, 71% also
achieved LTR, whereas only 20% of the PR patients did.
Conclusion: LS is safe and remains the most effective
second-line treatment for ITP. In our study, younger age
and response to preoperative steroids were predictive
factors for the long-term success of splenectomy.
Key Words: Immune thrombocytopenia, Laparoscopic
splenectomy, Response-predictive factors, Haematologi-
cal outcome, Long-term results.
INTRODUCTION
Idiopathic thrombocytopenic purpura (ITP) is an autoim-
mune hematologic disorder accompanied by low platelet
count and concomitant spontaneous bleeding. Low platelet
count is partly related to accelerated degradation in the
reticuloendothelial system and partly to decreased cell for-
mation in the bone marrow. The prevalence of the disease is
2–3 times higher in women and develops primarily between
the ages of 18 and 40. The disease is diagnosed by excluding
other causes of thrombocytopenia by reviewing medical
history, performing a physical examination, and studying
blood count and a peripheral blood smear. Definitions of
thrombocytopenia, criteria for starting treatment, response,
and therapy-refractory disease have long remained nonstan-
dardized. In 2009, an International Working Group (IWG)
offered a unified terminology.1 The term “immune thrombo-
cytopenia” was suggested instead of idiopathic thrombocy-
topenic purpura, and the cutoff value for the platelet count
was defined as 100 109/L. With regard to the immunologic
mechanism of ITP, first-line standard therapy consisted of
corticosteroids and intravenous immunoglobulins. If patients
do not respond to the first treatment or if the disease re-
sponds to the treatment but continuous therapy is required,
the disorder is called refractory ITP, and the administration of
a second-line therapy is indicated. This treatment may con-
sist of rituximab, thrombopoietin (TPO) receptor agonists, or
splenectomy. Of these 3 treatment options, splenectomy
provides the best and longest lasting results (an immediate
response rate approximately 80% and the rate of permanent
responders 60% for 5–10 years).2
The laparoscopic approach has been an acceptable sur-
gical method in the treatment of ITP for decades because
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of its numerous advantages. Hematologic outcomes of this
method are similar to those of conventional splenectomy.3
However, only limited publications are available on the
long-term results of splenectomy according to standard-
ized definitions and outcome criteria.4,5 Furthermore, with
regard to the fact that splenectomy is not effective imme-
diately in 15–25% of the cases and that relapse occurs in
one-third of the patients, it is important to determine
predictive factors to avoid unnecessary surgeries and to
plan the therapy. Several hypothetical factors have been
examined in predicting the outcome of splenectomy. Data
are available on the predictive value of age, response to
steroid therapy, perioperative platelet count, and charac-
teristics of platelet sequestration.6 Our intention was to
analyze the safety of splenectomy for ITP and to deter-
mine which perioperative parameters predict long-term
results when using evidence-based guidelines.
METHODS
The study was approved by the ethics committee of the
University of Szeged (No. WHO3932). From January 1,
2000, to January 1, 2015, 40 splenectomies were per-
formed for ITP. The patients had been treated in the
Hematology Department, and the surgical indication was
made on the basis of the hematology specialist’s report.
All the patients received corticosteroid therapy before
surgery, and splenectomy was performed in steroid-re-
fractory or steroid-dependent cases. Azathioprine or intra-
venous immunoglobulin (IVIG) therapy was administered
to10 patients before surgery, as well.
All the patients received vaccines against Streptococcus
pneumoniae, Neisseria meningitides, and Haemophilus in-
fluenzae. Surgeries were done with antibiotic prophylaxis,
with close control of hemostatus. The patients received pro-
phylactic low-molecular-weight heparin (LMWH) in the peri-
and postoperative period (for 30 days after discharge).
Surgical Technique
LS was performed with the patient lying in the lateral decu-
bitus position at 30° with the “anterolateral hanging spleen”
technique, according to Delaitre et al.7 During the learning
period, an Endo GIA stapler (Medtronic, Minneapolis, Min-
nesota, USA) was used to ligate the hilar vessels, followed by
individual vessel dissection and Hem-o-lok clip (Teleflex,
Morrisville, North Carolina, USA) ligation. The specimen was
placed in an EndoBag (Medtronic) with morcellation via the
lateral port (Figure 1). A drain was left in the abdominal
Figure 1. Steps in the laparoscopic splenectomy: (A) Exploration of the splenic hilum, (B) clipping of the splenic artery, (C) clipping
of the splenic vein, and (D) removal of the specimen in a specimen retrieval container.
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cavity after surgery in all cases, and the drain was removed
on the second postoperative day.
Follow-up and Hematological Response
Perioperative data were examined, such as preoperative
platelet count, duration of surgery, use of the laparoscopic
technique or conversion to open, mortality and morbidity,
and the weight of the specimen removed.
Average duration of long-term patient follow-up was
10.9  6.9 years. In accordance with the 2009 guidelines
issued by the IWG1 and the evidence-based guidelines
issued by the American Society of Hematology in 2011,8
response categories were complete response (CR; platelet
count over 100 109/L ); partial response (PR), defined as
at least a 2-fold increase compared to the baseline value (a
platelet count between 30 and 100  109/L); and nonre-
sponse (NR), defined as not reaching a 2-fold increase
compared to the baseline value (platelet count not in-
creasing over 30  109/L); and whether these changes
occurred within 30 days.
Patients were considered to be stable responders if the
response was maintained during the follow-up, no addi-
tional therapy was required, and there was no bleeding
requiring hospitalization after splenectomy. The case was
determined to be refractory ITP or loss of response if any
thrombocytopenic event occurred with platelet count
lower than 100  109/L in a previous responder patient
(CR), if the platelet count was below 30  109/L, or if the
platelet count was lower than twice the baseline value
(PR). Spontaneous bleeding or restarting medical therapy
was regarded as a loss of response, as well.
Finally, the predictive value of pre- and perioperative
parameters was analyzed for long-term results (CR, PR, NR
and loss of response).
Statistics
The t test and one-way ANOVA were used to compare the
mean values, as well as the Mann-Whitney and Kruskal-
Wallis tests in cases of non-normality. Categorical data
were analyzed using 2 and Fisher’s exact tests. The nor-
mal distribution of samples was assessed with the Kolm-
ogorov-Smirnov test. SPSS version 15.0 (IBM, Armonk,
New York, USA) was used for the statistical analyses.
RESULTS
The female-to-male ratio was 28:12. The average age of
the patients was 46.62  17.48 years, ITP was diagnosed
at an average age of 43 years, and the surgery was per-
formed an average of 25.1  5.73 months after the diag-
nosis. In all cases, the first-line treatment for ITP was
steroid therapy. Twenty-three cases (57.5%) were steroid
refractory, and 17 (42.5%) were steroid dependent. After
steroid treatment, 30 patients underwent splenectomy as
the second-line therapy. In 7 cases, azathioprine was ad-
ministered, and 3 patients received IVIG therapy as a
second-line therapy, followed by splenectomy.
Results of Surgery
In 4 of the 40 cases (10%), conversion to open surgery was
required. Three of the 4 conversions were required before
2004 during the learning curve (LS was introduced at our
clinic in 2000).There was no perioperative mortality. Two
patients (5%) required reoperation for bleeding. The av-
erage duration of the surgery was 113.5  62.71 minutes;
The literature defines the learning curve as 20 surgeries for
laparoscopic splenectomy,9 which was exceeded in 2006,
taking into account LS performed with other indications.
After this, the average duration of the surgeries decreased
significantly from 132 to 104 minutes (P  .032). The
average weight of the specimens removed was 174 
89.6 g. The average duration of postoperative care was
5.44  2.84 days. Perioperative morbidity occurred in 4
cases: 1 patient had pneumothorax, 1 experienced super-
ficial thrombophlebitis, and 2 had recurring fever.
Short- and Long-Term Hematological Results of
Splenectomy for ITP
The average preoperative platelet count was 66.7 
47.84  109/L. In cases requiring a platelet suspension
(n  27), it was administered during surgery after the
vessels of the spleen were clipped. On the third postop-
erative day, the average platelet count was 148.4 93.7
109/L. Based on the postoperative platelet counts, CR
occurred in 28 (70%) cases and PR in 5 (12.5%). A total of
82.5% of the patients responded to splenectomy in accor-
dance with the guidelines. Seven (17.5%) patients showed
no response.
Follow-up lasted an average of 10.9  6.9 years. During
this time, 2 patients died, 5 and 7 years after the splenec-
tomy. Cause of death was a cardiac event in an 84-year-
old patient and neoplasm was the cause of death in a
56-year-old patient. During the follow-up, 21 (63.6%) of
the responders (CR PR 33) had a long-term response.
Patients with a CR experienced a long-term response in
20/28 cases (71%), whereas a long-term response was
achieved in 1 of 5 cases (20%) among the PR patients.
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Relapse (restarting medical therapy, spontaneous bleed-
ing, platelet count  30  109/L) occurred 12.5  7.3
months on average after the splenectomy. The relapse rate
was significantly higher in the PR group compared with
the CR patients (80% vs 28.6%). PR cases experienced
relapse sooner compared with the CR patients (9.7 vs 18.6
months; P  .001).
The 12 patients with relapse and the 7 nonresponder
patients underwent steroid, TPO receptor agonist (romi-
plostim and eltrombopag), azathioprine, or IVIG therapy
as further treatment.
The general results of the patients are summarized in
Table 1.
Predictive Factors for Short- and Long-Term
Response
Based on the results above, we examined which known
perioperative factors and parameters predicted short- and
long-term success (Table 2).
All the patients operated on as steroid dependent (n 17)
were CR, whereas patients operated on because they were
steroid refractory were classified as CR (n  11), PR (n 
5), and NR (n  7). From a different perspective, all PR
and NR patients fell into the preoperative steroid-refrac-
tory group. Significantly more NR patients were in the
steroid-refractory group (0/17 vs 7/23; P  .027).
Long-term results suggest that, among the steroid-depen-
dent patients (n  17), 12 had a persistent response
(70.6%), whereas 9 of 16 patients (56.3%) in the steroid-
refractory group were persistent NRs.
The average age of the CR group was 42.79  13.24, that
of the PR group was 49.2  18.32, and that of the NR
group was 60.14 24.21 years. Among the patients below
the age of 50 years (n  22), 17 were CR, 3 were PR, and
2 were NR. Among the patients over the age of 50 years
(n  18), 11 were CR, 2 were PR, and 5 were NR. There-
fore, in the younger group, 9% of the patients were NR;
this rate was 28% among the patients in the older group
(2/22 vs. 5/18; P  .023).
Long-term follow-up showed that the average age of per-
sistent responders was 42.6  16.5, and that of patients
with relapse was 45.75  21.3 years. Among the patients
below the age of 50 years, 14 of 20 were persistent re-
sponders (70%), whereas this rate was 7 of 13 among
older patients (53.8%) (nonsignificant [NS]).
Of the patients whose preoperative platelet count was
below 30  109/L (n  16), 7 were in the CR group
(43.75%), 5 were in the PR group (31.25%), and 4 were
in the NR group (25%). Among the patients with a
platelet count over 30  109/L (n  24), 21 were in the
CR group (87.5%), and 3 were in the NR group (12.5%)
(NS).
Of the 10 patients who had undergone splenectomy as a
third- and not a second-line therapy (after azathioprine or
IVIG therapy), the surgery was performed after an average
of 17.75  3.43 months after the diagnosis, which was
unexpectedly shorter compared with the average value of
all the patients. Of these 10 patients, 6 were CR, 2 were PR,
and 2 were NR (NS).
In summary, response to first-line steroid therapy (depen-
dency) (P  .027) and younger age (P  .023) proved
to be more effective in predicting short-term efficacy of
splenectomy based on logistic regression analysis (Ta-
ble 3).
Table 1.
General Results of Splenectomy in Patients With ITP
CR (Plt 100  109/L) PR (Plt 30–100  109/L) NR (Plt 30  109/L)
Patients, n (%) 28 (70%) 5 (12.5%) 7 (17.5%)
Age (years) 42.79  13.24 49.2  18.32 60.14  24.21
Gender (F/M) 18/10 5/0 5/2
Splenic weight (g) 160.13  12.47 206.25  10.21 229  9.62
Postoperative increase in thrombocyte count (103/L) 122.5  34.2 50.8  11.5 8  9.62
Relapse rate, n (%) 8/28 (28.6%) 4/5 (80%)
Median time to relapse (months) 18.6 9.7
N  40.
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None of the parameters examined and listed in Table 2
predicted long-term hematologic outcomes, although we
confirmed that the extent of the immediate response was
a good predictor of long-term results, which is often de-
scribed in the literature as well: 71% long-term response
for CR and 20% for PR (P  .001).
DISCUSSION
Splenectomy in the Treatment of ITP
In steroid-refractory and steroid-dependent ITP, splenec-
tomy provides the best and most permanent results as a
second-line therapy compared with medicinal therapy
(TPO mimetics and rituximab).6,10
A splenectomy exerts its effect by removing the primary
site of platelet destruction and partly by removing an
important site of antiplatelet antibody production, with
the response rate reported at an average of 80% and the
rate of permanent responders 60%.4,6
In a systematic review of 135 cases published in 2004, the
response rate was 88%, and a complete response was
found in 66% of the patients, with a median follow-up
duration of 28 months.3 In a systematic review of laparo-
scopic splenectomies published in 2009, the conversion
rate of the 1223 patients examined was 5.6%, and the
success rate was 72%.11
In our study, CR was found in 70% (n  28) and PR
occurred in 12.5% (n  5) of the cases; that is, a total of
82.5% of the patients responded to splenectomy per-
formed in accordance with the guidelines. This rate was
not influenced by whether the splenectomy was per-
formed as a second- or third-line therapy. In patients
treated with azathioprine or IVIG after steroid treatment,
CR was achieved in 60% after splenectomy, PR occurred in
20% after the surgery, and NR in 20%. These rates are
consistent with the results found after examining all the
patients; therefore, previous treatment did not influence
the efficacy of the splenectomy.
After a follow-up of an average of 9.92 years, 63.6% of the
responder patients (CR  PR  33) had a long-term
response (n  21), which correlates with the known rate
of one-third of patients showing a response initially and
developing a relapse later.3,10
If relapse occurs after splenectomy, based on data in the
literature, it takes place at 12–48 months. After this time, it
occurs only sporadically.10 Our study confirmed this re-
Table 2.
Possible Predictive Factors
CR (Plt 100  109/L)
(n  28)
PR (Plt 30–100  109/L)
(n  5)
NR (Plt 30  109/L
(n  7)
Preoperative steroids, n (%)
Dependent (n  17) 17 (100%) 0 0
Refractory (n  23) 11 (47.8) 5 (21.7) 7 (30.4)
Age
50 years (n  22) 17 (77.3) 3 (13.6) 2 (9)
50 years (n  18) 11 (61) 2 (11) 5 (27.8)
Preoperative platelet count
30  109/L (n  16) 7 (43.75) 5 (31.25) 4 (25)
30  109/L (n  24) 21 (87.5) 0 3 (12.5)
Surgery indication
Second-line therapy (n  30) 22 (73.3) 3 (10) 5 (16.7)
Third-line therapy (n  10) 6 (60) 2 (20) 2 (20)
Data are number of patients (percentage of total group).
Table 3.
Results of Logistic Regression Analysis in the NR Subgroups
Factor OR 95% CI P
Preoperative steroids 1.265 1.063–1.496 0.027
Age 1.359 1.0370–1.771 0.023
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sult. In our patients, relapse developed after an average of
12.5 months, and no relapse was detected after 47 months.
Alternative options for second-line therapy are medica-
tions such as rituximab or TPO-RAs. The long-term effi-
cacy of these treatments is less than that of splenectomy.
Rituximab (a chimeric monoclonal antibody against
CD20) has an immediate efficacy of 50–65%, although
relapse occurs frequently; therefore, the long-term re-
sponse after 12 and 24 months is only between 20 and
30%. In 2015, a multicenter randomized, double-blind,
placebo-controlled study was published, describing a
long-term response rate for rituximab similar to that for
the placebo.12
A study published in 2016 comparing the results for sple-
nectomy, and rituximab therapy found splenectomy to be
more effective (the 30-month primary outcome–free sur-
vival rate was 84–86% for splenectomy vs 47% for ritux-
imab; P  .0002).5
TPO agonists exert their effect by enhancing platelet pro-
duction, not by modulating the immune system. TPO
agonists stimulate platelet production of megakaryocytes.
A response rate of 59–80% can be achieved with these
medications; however, a great disadvantage of these prod-
ucts is that they are expensive and that permanent treat-
ment is required, because withdrawal of therapy leads to
the recurrence of thrombocytopenia.13
With regard to the splenectomy technique, several publi-
cations are available comparing LS and open splenectomy
(OS). It can be concluded that LS and OS are similarly
effective from a hematologic point of view.8 Qu et al4
performed OS and LS, and found no significant difference
for relapse-free survival during a 36-month follow-up
(86% for OS vs 91% for LS; P .792). Chater et al5 reached
similar results for 30-month event-free survival, with no
difference found between LS and OS (86% vs 84%). In a
systematic review conducted on 47 case series in 2004, a
lower mortality rate (1% vs 0.2%) and fewer complications
(12.9% vs 9.6%) were observed for LS vs OS.3 The main
limitation of the laparoscopic technique is splenomegaly
(a spleen weighing over 500 g), although our previous
results showed that laparoscopic splenectomy was not
contraindicated, even in the case of extreme splenomeg-
aly (a spleen weighing over 2000 g).14 Splenomegaly caus-
ing technical difficulties is not characteristic of ITP; there-
fore, this limiting factor is not common either.
Potential Complications of Splenectomy
With second-line medicinal therapy, the possibility of
peri- or postoperative or late complications of splenec-
tomy is often emphasized.10 In our study, complications
were observed after splenectomy in only 2 cases, with the
patients experiencing bleeding that required reoperation.
No complication occurred besides reoperation due to
bleeding in 5% of the patients, although surgery was
performed with a platelet count of 5000/mL in 3 of them.
Several publications analyzed the safety of surgeries per-
formed in patients with a low platelet count. Cai et al15
compared the results of LS in patients with a platelet count
below 10  109/L (grade 1) with those of patients oper-
ated on with a higher platelet count (grade 2: 10–30 
109/L, and grade 3:30 109/L). Our results showed that
blood loss and the number of complications was not
significantly increased, and hospital stay was not signifi-
cantly prolonged in patients operated on with a lower
platelet count. Wu et al16 examined surgical patients with
a platelet count below 20 109/L and found no difference
with regard to the outcome in patients who did not re-
ceive preoperative platelet transfusion compared with
those who did. In our case, reoperation was performed in
2 patients with platelet counts of 36 and 42  109/L.
No pancreatitis, perioperative infection, or suppuration
occurred in our series. Patients who have splenectomy are
more susceptible to infections and vascular complications
in the long term. Increased risk of infections is confirmed
in patients who undergo splenectomy. In a Danish cohort
study, susceptibility to infections among 3,812 patients
who had splenectomy was compared with that of 8,310
matched nonsplenectomized patients and that of 38,120
control patients. The risk rate for sepsis increased 14-fold
during the first year in patients who had splenectomy
compared with the general population; after 1 year, the
risk rate decreased to 4-fold. Comparing the results with
those of nonsplenectomized patients with ITP, an in-
creased risk rate of sepsis was found only during the first
90 days.17 Perioperative vaccination, patient education on
the risk of overwhelming sepsis, and use of antibiotic
prophylaxis greatly aid in preventing septic complica-
tions. For instance, Vianelli et al18 examined 402 patients
in their study and did not report sepsis-related mortality.
In our study, no sepsis-related mortality occurred.
In addition to the risk of infection, there is potential for
vascular complications. The thrombocytopenia in ITP
makes patients susceptible to thromboembolization, ac-
cording to data in the literature,19 and splenectomy in-
creases the risk of venous thromboembolization.20 In our
study, with prophylactic LMWH administered perma-
nently (35–40 days), no deep venous thrombosis was
confirmed; only one superficial thrombophlebitis was
identified.
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In our investigation, surgery-related morbidity was not
significant, and because of potential risks, estimation of
response is very useful in considering surgery based on
predictive parameters.
Predictive Factors of the Efficacy of Splenectomy
There are several publications about predictive factors
that may be determined before splenectomy and that may
be used to predict long-term results of surgery, as well.
The most widely accepted predictive factors are younger
age, steroid dependency, nonrefractory status, higher
platelet count before surgery, and splenic sequestration.
In our study, no data were available for splenic seques-
tration, so the other factors were analyzed for predictive
value.
Our study confirmed the predictive value of younger age
described in the literature.21–22
The average age of the CR group was 42.79 13.24 years,
that of the PR group was 49.2  18.32 years, and that of
the NR group was 60.14  24.21 years. Long-term fol-
low-up for persistent responders showed an average age
of 42.6  16.5 years, and patients developing a relapse
were 45.75  21.3 years of age on average. The response
rate for patients below the age of 50 years (n  22) was
90.1% (77.3% CR and 13.6% PR), whereas this rate was
72.2% (61.1% CR and 11.1% PR) in patients over the age of
50 (n  18). There were significantly more NR patients in
the older group (P  .023). In addition, 70% of the pa-
tients below the age of 50 showing an immediate re-
sponse also had a long-term response, whereas this rate
was only 53.8% in older patients. Shojaiefard et al21 ob-
tained results similar to ours; in their study, patients below
the age of 52 responded to splenectomy more positively
compared to elderly patients (P  .01). Fabris et al22
confirmed age below 40 years to be the only major pre-
dictive factor in a similar investigation. Opposite results
have been reported in the literature, as well: Vianelli et
al10 studied 233 patients for more than 10 years and found
no link between age and response to splenectomy, and,
similarly, Rijcken et al23 had negative results for the pre-
dictive value of age in their examination of 72 patients.
Several studies have analyzed the predictive role of re-
sponse to preoperative steroids.23,24 In our study, all the
surgical patients who were steroid dependent (n  17)
were in the CR group, although all the PR (n  5) and NR
(n  7) patients fell into the preoperative steroid-refrac-
tory group. There were significantly more NR patients in
the steroid-refractory group (P  .027). In the case of
patients showing a persistent response (n  21), 12 were
steroid dependent and 9 were steroid refractory; in the
loss-of-response group (n  12), 5 patients were steroid
dependent and 7 were steroid refractory. Rijcken et al23
and Aleem24 among others, found response to steroids to
be a predictive factor in their studies.
Perhaps the least controversial fact is that CR significantly
predicts the probability of a long-term stable response.23,25
Wang et al26 followed up 92 patients and found platelet
count in the third postoperative month to be an indepen-
dent predictor of long-term outcome. Rijcken et al23 found
a greater increase in platelet count in the postoperative
period (150,000/L) to be a predictor of long-term re-
sponse. Montalvo et al27 examined 150 patients and found
an immediate response after surgery (150,000) to be the
1-year CR predictor. In addition, Vianelli et al10 followed
up 233 patents for at least 10 years and confirmed no
stable predictors of long-term response. During our fol-
low-up, we reached the same findings. Results were
found to be permanent in 71% of the CR patients, but a
long-term response occurred in only 20% of the patients in
the PR group.
In the future, lifespan and sequestration studies of plate-
lets labelled with indium would be useful (if the literature
data show that splenectomy is effective in 90% of cases),25
although such data were not available in our study.
Finally, we compared our results to the literature data and
examined both the number of published studies that used
the consensus guidelines to follow up on patients in the
long term after laparoscopic splenectomy since the 2011
introduction of the standardized guidelines8 and the pre-
dictive factors in these publications.
Xu et al28 analyzed 114 patients in whom age and post-
operative peak platelet count were independently associ-
ated with the response. Vecchio et al29 also examined
patients with laparoscopic and open surgeries for a 2015
publication and found that a higher increase in postoper-
ative platelet count may be predicted in patients with a
low preoperative platelet count. In the investigation by
Rijcken et al23 with 72 patients (noted above), periopera-
tive platelet counts were predictive factors of long-term
response. Navez et al30 studied 82 patients in 2014, pri-
marily examining the predictive value of platelet seques-
tration; the platelet sequestration site was not found to be
a predictive factor, but age was. Montalvo et al27 reviewed
data on 150 patients and found no predictive factors of
long-term response besides immediate CR (response
150,000 platelets/mL during the first week). In 2013,
Wang et al26 reported that platelet count in the third
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postoperative month was a significant independent pre-
dictor of long-term favorable hematologic outcomes.
In summary, literature data have been exceedingly heter-
ogeneous with regard to predictive factors, even since the
consensus guidelines were published. In addition, poten-
tially prospective studies are necessary to determine pre-
dictive factors. Furthermore, long-term follow-up of pa-
tients with various imaging techniques is important to
screen the accessory spleen and its possible role in non-
responsive and refractory ITP.
CONCLUSION
Although several medications are available for second-
line ITP therapy, splenectomy provides the longest lasting
results. LS is the gold standard, as it can be performed
safely and with great efficacy in centers experienced in the
technique. In our study, young age and a preoperative
response to steroids (steroid-dependent cases) were pos-
itive predictors for the success of splenectomy. In the case
of an immediate complete response to splenectomy, re-
lapse occurred significantly less often during long-term
follow-up.
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